Metastatic Uveal Melanoma (MUM) Market Trends
As per the Skin Cancer Foundation, Uveal melanoma, the most common primary intraocular malignancy in adults, represents approximately five percent of all melanomas recorded in the United States. The incidence of uveal melanoma has remained relatively constant, between five and six cases per million people in the United States and Europe. These melanomas vary in frequency depending on their location in the uveal tract, i.e., approximately five percent occur in the iris, five percent in the ciliary body and at least 90% in the choroid.
According to a study conducted by Terai et al. titled “Immunological aspect of the liver and metastatic uveal melanoma” highlighted that Uveal (eye) melanoma was the most common primary eye malignancy in adults. Despite optimal treatments for primary uveal melanoma, up to 50% of patients subsequently develop systemic metastasis, often in the liver. Once hepatic metastasis develops, the survival of patients was generally short, and currently available treatments failed to show meaningful improvement of survival.
DelveInsight's "Metastatic Uveal Melanoma (MUM) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Metastatic Uveal Melanoma (MUM) Market, historical and forecasted epidemiology, the pipeline insight as well as the Metastatic Uveal Melanoma (MUM) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Metastatic Uveal Melanoma (MUM) Market Trends Analysis
The Metastatic Uveal Melanoma (MUM) market size is expected to increase during the forecast period owing to the launch of upcoming therapies in the market. The Metastatic Uveal Melanoma (MUM) market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Metastatic Uveal Melanoma (MUM) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
Metastatic Uveal Melanoma (MUM) Epidemiology Forecast
The Metastatic Uveal Melanoma (MUM) epidemiology section covers insights about historical and current Metastatic Uveal Melanoma (MUM) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Metastatic Uveal Melanoma (MUM) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Metastatic Uveal Melanoma (MUM) Pipeline Analysis
The Metastatic Uveal Melanoma (MUM) Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Metastatic Uveal Melanoma (MUM) market or expected to get launched in the market during the study period. The analysis covers the Metastatic Uveal Melanoma (MUM) market uptake by drugs, patient uptake by therapies, and drug sales.
Currently, no standard of care exists to guide management of Metastatic Uveal Melanoma. In Uveal Melanoma the most common site of metastatic disease in the liver, and a number of hepatic-directed therapies are available including surgery, radiation therapy, radiofrequency ablation, embolization, and laser therapy. The Metastatic Uveal Melanoma (MUM) pipeline is quite robust with several products available in the developmental stage. As per clinical trial registries, there are several key players involved in the development of promising combination products.
Some of the key Metastatic Uveal Melanoma (MUM) companies involved in the development of therapeutic products include:
Delcath Systems
Merck
Syndax Pharmaceuticals
BioMed Valley Discoveries
Bristol-Myers Squibb
Bellicum Pharmaceuticals
And many others.
Source: Metastatic Uveal Melanoma (MUM) Market Trends